Trump signed an executive order on April 18 directing federal health agencies to accelerate psychedelic therapy research for military veterans, and the response from lawmakers was fast and, in some cases, genuinely surprising.

The order tasks the Department of Veterans Affairs and the FDA’s clinical trial framework with coordinating alongside the Department of Health and Human Services and the Food and Drug Administration to move clinical trials forward on psychedelic treatments, ibogaine chief among them. Sen. Dave McCormick framed the order as clearing bureaucratic obstacles and pointed to S. 4031, legislation he co-introduced with Sen. Ruben Gallego, as a parallel push on Capitol Hill.

It’s worth pausing on that pairing. McCormick is a Republican from Pennsylvania. Gallego is a Democrat from Arizona. That kind of joint authorship doesn’t happen by accident, and it’s a signal that psychedelic therapy for veterans has built real coalitions across the aisle.

Rep. Lou Correa, a Democrat from California, didn’t soften his support one bit. “President Trump and I agree on this one,” Correa said, adding that the treatments could address PTSD, mental health disorders, alcoholism, drug addiction, Alzheimer’s and other conditions. In 2026, that’s a notable statement. Democratic endorsements of Trump actions on Capitol Hill are rare, and Correa’s came without hedging or qualification.

Sen. Lindsey Graham called the move “a very good decision by President Trump” and said he “totally supports” expanding alternative treatment options for veterans dealing with mental health conditions. Sen. Tim Sheehy of Montana went straight at the moral argument: “It is long overdue that we open up all available avenues to provide warriors the care they need so that when they return from war, they can carry on life as Veterans, not Victims,” Sheehy said.

Rep. Dan Crenshaw, a Navy SEAL who lost an eye in Afghanistan, brought it personal. He’s seen ibogaine work on friends who were struggling. “Countless lives could be saved by this,” he said. Rep. Morgan Luttrell, who attended the White House signing, posted a photo with his brother Marcus Luttrell, the “Lone Survivor” author. “What a massive step forward for our veterans,” Luttrell wrote. Rep. Michael McCaul issued a joint statement with Luttrell, though the full text hadn’t been released.

The reactions from federal lawmakers span a political range that would’ve been unthinkable a few years back. It’s 2026, and the veterans’ mental health crisis has become one of the few issues that can still cut through partisan noise.

So what does any of this mean for California? Quite a bit, actually.

The state’s already running some of the most active psychedelic research programs in the country. There are roughly 1.8 million veterans living in California, and the demand for alternative treatments has been building since at least 2022, when serious legislative conversations about psychedelic reform began picking up momentum in Sacramento. That patient population is enormous, and it’s concentrated in counties, including ones near the Emerald Triangle, where cannabis policy has already reshaped local economies.

Here’s the uncomfortable parallel that cannabis growers and regulators in Humboldt and Mendocino counties know well: when California rushed cannabis commercialization ahead of the science and the regulatory infrastructure, it created 18 months of chaos that small farmers are still paying for. Oversupply. Licensing backlogs. A legacy market that wouldn’t die because the legal one didn’t work. The federal approach here, using the FDA’s clinical trial process rather than fast-tracking commercial access, suggests somebody studied that lesson.

That doesn’t mean psychedelic policy won’t eventually hit California’s regulatory machine and come out looking different than intended. The state has a track record. But the order’s framing around clinical trials and federal coordination gives researchers and reform advocates something they can work with, a federal scaffold that California’s programs can attach to.

For 3 years, advocates here have been arguing that California could lead on psychedelic therapy the same way it led on medical cannabis. The April 18 order hands them some federal momentum to work with. Whether Sacramento knows what to do with it is a different question entirely.